Natera, Inc. (NASDAQ:NTRA) CFO Sells $73,422.08 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 608 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08. Following the completion of the sale, the chief financial officer now directly owns 74,014 shares of the company's stock, valued at approximately $8,937,930.64. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Price Performance

Shares of Natera stock traded down $0.55 during mid-day trading on Tuesday, reaching $119.95. 718,795 shares of the stock were exchanged, compared to its average volume of 1,334,780. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a market cap of $14.73 billion, a price-to-earnings ratio of -38.45 and a beta of 1.53. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $133.54. The firm has a 50-day simple moving average of $123.43 and a 200 day simple moving average of $110.98.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analysts' expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company's quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.97) EPS. On average, sell-side analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lecap Asset Management Ltd. grew its position in shares of Natera by 8.2% during the 3rd quarter. Lecap Asset Management Ltd. now owns 7,003 shares of the medical research company's stock worth $889,000 after buying an additional 531 shares during the period. Private Advisor Group LLC grew its position in shares of Natera by 5.2% during the 3rd quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company's stock worth $346,000 after buying an additional 135 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock worth $156,092,000 after buying an additional 246,246 shares during the period. Moss Adams Wealth Advisors LLC grew its position in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company's stock worth $336,000 after buying an additional 135 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of Natera during the 3rd quarter worth approximately $249,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NTRA shares. BTIG Research raised their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a report on Friday, August 9th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a report on Friday, August 9th. Canaccord Genuity Group raised their price objective on shares of Natera from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Tuesday, August 27th. Stephens reaffirmed an "overweight" rating and set a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Finally, StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.